RxDoctor Payments Data

Bobby Ellis, MD

Internal Medicine · Ardmore, OKNPI 1679595144

Payments from drug & device makers

$450in general payments, 2019–2025

Across 28 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$53
  • GSK$53
  • Sanofi-aventis U.S. LLC$52
  • Bayer$46
  • Pfizer$35
  • Exact Sciences$29
  • plus $182 from 9 others

What the payments were for

  • Food & beverage$450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$450 in reported general payments places this provider in the 55th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$150,869
Medicare patients
406
Services billed
1,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide151$174,242
EliquisApixaban218$161,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$76,760
JanuviaSitagliptin Phosphate56$48,546
TriumeqAbacavir/Dolutegravir/Lamivudi11$47,716
FarxigaDapagliflozin Propanediol29$39,659
JardianceEmpagliflozin30$34,014
TrulicityDulaglutide21$31,653
XareltoRivaroxaban28$24,765
MounjaroTirzepatide16$18,313
Breo ElliptaFluticasone/Vilanterol32$18,037
LinzessLinaclotide26$16,559
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$12,810
Combivent RespimatIpratropium/Albuterol Sulfate25$12,417
TradjentaLinagliptin16$12,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$174,242151 claims
PfizerEliquis$35$161,340218 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$53$100,619131 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$22$58,66971 claims
Lilly USA, LLCTrulicity, Mounjaro$27$49,96637 claims
Johnson & JohnsonXarelto$23$24,76528 claims
AbbVieLinzess$53$16,55926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →